. Author manuscript; available in PMC: 2014 Jan 7.

Published in final edited form as: Pharmacotherapy. 2012 Apr;32(4):323–332. doi: 10.1002/PHAR.1048

Table 1. Model Parameters Used in Determining Cost-Effectiveness of Antiplatelet Therapy Selection.

Parameter	Base-Case Value (range)
UM or EM^{3, 6, 25–27, 29, 30}	0.730 (0.680–0.738)^a
IM or PM^{4, 6, 26, 27}	0.270 (0.261–0.319)^a^, ^b
Cardiovascular event for UM or EM with clopidogrel^{3, 25, 26}	0.080 (0.059–0.139)
Noncardiovascular event (bleeding) for UM or EM with clopidogrel³	0.030
Cardiovascular event for IM or PM with prasugrel⁴	0.085
Noncardiovascular event (bleeding) for IM or PM with prasugrel⁴	0.045
Cardiovascular event with clopidogrel^{12, 28}	0.121 (0.092–0.150)^b
Cardiovascular event with prasugrel^{12, 28}	0.099 (0.057–0.141)^b
Noncardiovascular event (bleeding) with clopidogrel^{12, 28}	0.038 (0.022–0.054)^c
Noncardiovascular event (bleeding) with prasugrel^{12, 28}	0.050 (0.022–0.078)^c
Genotyping CYP2C19^{17, 18}	$310^d
Uncomplicated percutaneous coronary intervention¹⁹	$18,000^d
Branded clopidogrel 75 mg/day for 15 mo²⁰	$2660^d
Prasugrel 10 mg/day for 15 mo²⁰	$2800^d
Bleeding event²¹	$19,360
Cardiovascular death²²	$23,760^d
Nonfatal myocardialinfarction²²	$40,970^d
Nonfatal stroke²²	$27,314^d

Costs are reported in 2011 U.S. dollars.

Cardiovascular events were defined as a composite of cardiovascular deaths, nonfatal myocardial infarction, and nonfatal stroke. UM or EM = ultrarapid or extensive metabolizer; IM or PM = intermediate or poor metabolizer; CYP2C19 = cytochrome P450 2C19.

Values reflect IMs or PMs for predominantly Caucasian populations.

Value of lower range imputed from upper range.

Value of upper range imputed from lower range.

All costs reflect adjusted August 2011 costs discounted at 5% to account for future value.